Skip to main content

Table 2 Oncological outcome comparison

From: Comparisons of oncological and functional outcomes among radical retropubic prostatectomy, high dose rate brachytherapy, cryoablation and high-intensity focused ultrasound for localized prostate cancer

Variable

RRP (N = 97)

HDR (N = 161)

Cryo (N = 114)

HIFU (N = 120)

P value

Follow-up duration, months (mean ± SD)

34.68 ± 12.45

33.54 ± 14.95

33.46 ± 14.38

32.68 ± 11.87

0.338

PSA nadir, ng/mL (mean ± SD)

0.40 ± 1.10

0.94 ± 1.59

0.81 ± 2.29

0.64 ± 1.77

0.031

PSA biochemical recurrence, N (%)

47 (48.5)

88 (54.7)

36 (31.6)

29 (24.2)

0.000

Low risk, N (%)

2 (22.2)

1 (16.7)

2 (10.5)

1 (6.7)

0.699

Intermediate risk, N (%)

3 (30.0)

11 (34.4)

3 (12.5)

4 (8.5)

0.020

High risk, N (%)

42 (53.8)

76 (61.8)

31 (43.7)

24 (41.4)

0.024

PSA biochemical recurrence-free survival, months (mean ± SD)

22.13 ± 14.85

21.17 ± 14.49

26.39 ± 12.53

27.66 ± 13.72

0.000

Salvage treatment free, N (%)

59 (60.8)

75 (46.7)

82 (71.9)

84 (70.0)

0.000

Metastasis free, N (%)

92 (94.8)

146 (90.7)

113 (99.1)

119 (99.2)

0.001

  1. RRP radical retropubic prostatectomy, HDR high dose rate brachytherapy, Cryo cryoablation, HIFU high-intensity focused ultrasound, SD standard deviation, PSA prostate-specific antigen